CORDIS
EU research results

CORDIS

English EN
TargetIng novel MEchanisms of Resolution in inflammation

TargetIng novel MEchanisms of Resolution in inflammation

Objective

Resolution of inflammation is a key determinant of pathology, and an active process which involves diverse pathways and molecules. The general objective of the TIMER Consortium is to identify and validate new molecules involved in the resolution of inflammation as a basis for the development of innovative therapeutic strategies in chronic inflammatory and autoimmune diseases. The project will involve discovery of new natural or synthetic “pro-resolving” molecules for plant and animals and investigation on endogenous inflammation “pro-resolving” mechanisms identified by various partners of the Consortium, including atypical chemokine receptors, decoy receptors, and microRNA. Tapping resources of natural compounds will be a major thrust. Efforts will be mainly focused on the regulation by “pro-resolving” agents on two molecular systems of key relevance in inflammation: the chemokine system, which regulates recruitment, permanence and egress of leukocyte in tissues; and the TLR/IL-1R system, which is central for the activation of infiltrating leukocytes.
To this purpose, the project will capitalize on, and bring added value to a strong tradition of the Consortium in the fields of: leukocyte recruitment and activation; negative regulators of inflammation; industrial-academic collaboration; identification and characterization of innovative inhibitors of natural origin; European-Brazilian collaboration.

Coordinator

FONDAZIONE HUMANITAS PER LA RICERCA

Address

Via Manzoni
20089 Rozzano

Italy

Activity type

Research Organisations

EU Contribution

€ 597 503,54

Administrative Contact

Danilo Petroni (Dr.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

DOMPE SPA

Italy

UNIVERSIDADE FEDERAL DE MINAS GERAIS

Brazil

EU Contribution

€ 250 500

UNIVERSIDADE DE SAO PAULO

Brazil

EU Contribution

€ 220 800

FUNDACAO OSWALDO CRUZ

Brazil

EU Contribution

€ 222 000

FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA

Switzerland

EU Contribution

€ 363 600

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 357 600

TELORMEDIX SA

Switzerland

EU Contribution

€ 289 696,46

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 297 600

MERCK SERONO SA

Switzerland

EU Contribution

€ 36 963

ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU

Italy

EU Contribution

€ 100 000

NOVIMMUNE SA

Switzerland

EU Contribution

€ 163 037

DOMPE FARMACEUTICI SPA

Italy

EU Contribution

€ 100 000

Project information

Grant agreement ID: 281608

Status

Closed project

  • Start date

    1 January 2012

  • End date

    31 December 2015

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 989 175,67

  • EU contribution

    € 2 999 300

Coordinated by:

FONDAZIONE HUMANITAS PER LA RICERCA

Italy